These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9919353)

  • 21. Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence.
    Escames G; Acuña-Castroviejo D; López LC; Tan DX; Maldonado MD; Sánchez-Hidalgo M; León J; Reiter RJ
    J Pharm Pharmacol; 2006 Sep; 58(9):1153-65. PubMed ID: 16945173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Issues in the adjunct therapy of severe sepsis.
    Verhoef J; Hustinx WM; Frasa H; Hoepelman AI
    J Antimicrob Chemother; 1996 Aug; 38(2):167-82. PubMed ID: 8877531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.
    Ohlsson K; Björk P; Bergenfeldt M; Hageman R; Thompson RC
    Nature; 1990 Dec; 348(6301):550-2. PubMed ID: 2147233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of sepsis.
    Evans TJ; Cohen J
    J Med Microbiol; 1993 Apr; 38(4):237-9. PubMed ID: 8474114
    [No Abstract]   [Full Text] [Related]  

  • 25. [SSC International Guideline 2016 - Management of Sepsis and Septic Shock].
    Rahmel T
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2018 Feb; 53(2):142-148. PubMed ID: 29426052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock.
    Wolff SM
    N Engl J Med; 1991 Feb; 324(7):486-8. PubMed ID: 1988835
    [No Abstract]   [Full Text] [Related]  

  • 27. A novel treatment strategy for sepsis and septic shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid.
    Tunctan B; Korkmaz B; Sari AN; Kacan M; Unsal D; Serin MS; Buharalioglu CK; Sahan-Firat S; Schunck WH; Falck JR; Malik KU
    Antiinflamm Antiallergy Agents Med Chem; 2012; 11(2):121-50. PubMed ID: 23013331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of direct hemoperfusion using polymyxin B immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock.
    Kanesaka S; Sasaki J; Kuzume M; Narihara K; Takahashi Y
    Int J Artif Organs; 2008 Oct; 31(10):891-7. PubMed ID: 19009507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiendotoxin therapy in sepsis.
    Colletti RC; Dew RB; Goulart AE
    Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
    Balk RA
    Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory therapies in sepsis.
    Kox WJ; Volk T; Kox SN; Volk HD
    Intensive Care Med; 2000; 26 Suppl 1():S124-8. PubMed ID: 10786969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy.
    De Kock I; Van Daele C; Poelaert J
    Acta Clin Belg; 2010; 65(5):323-9. PubMed ID: 21128559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunotherapy in sepsis syndrome].
    Schellekens JF; van Deventer SJ
    Ned Tijdschr Geneeskd; 1992 May; 136(22):1050-4. PubMed ID: 1603159
    [No Abstract]   [Full Text] [Related]  

  • 36. Endotoxin, sepsis, and the primrose path.
    O'Reilly M; Newcomb DE; Remick D
    Shock; 1999 Dec; 12(6):411-20. PubMed ID: 10588508
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
    Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Problems and perspective approaches to correction of mediator response in sepsis].
    Mironov PI; Rudnov VA
    Anesteziol Reanimatol; 1999; (3):54-9. PubMed ID: 10458039
    [No Abstract]   [Full Text] [Related]  

  • 39. [The pathophysiological and intensive care-resuscitation aspects of septic shock].
    Vasilev D; Karadimov D
    Khirurgiia (Sofiia); 1996; 49(4):9-11. PubMed ID: 8968133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis.
    Opal SM
    Int J Med Microbiol; 2007 Sep; 297(5):365-77. PubMed ID: 17452016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.